We have rarely seen a poll flip in such a short time! Shortly after Trump took over his office as president of the United States of America, most of the pollees believed that nobody can say for sure yet what effect the Trump presidency would have on biotech stocks. However, in mid-February, an overwhelming majority voted that it would not be good news in the long run, instead. At the end, the option “No” collected most votes with almost 54% of all votes, while less than 20% said “Yes”.
Read the opinion of Frédéric Gomez, Analyst at Pharmium Security: “Will the Trump effect last?”